A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02577-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Hiroshi Fujiwara und 26 weiteren Autor:innen. Beteiligte Einrichtung: Shizuoka City Shizuoka Hospital, Shizuoka, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.
Abstract (Originalsprache)
Background
The treatment and prognosis of de novo metastatic hormone-sensitive prostate cancer (mHSPC) vary. We established and validated a novel prognostic model for predicting cancer-specific survival (CSS) in patients with mHSPC using retrospective data from a contemporary cohort.
Methods
1092 Japanese patients diagnosed with de novo mHSPC between 2014 and 2020 were registered. The patients treated with androgen deprivation therapy and first-generation anti-androgens (ADT/CAB) were assigned to the Discovery ( N = 467) or Validation ( N = 328) cohorts. Those treated with ADT and androgen-receptor signaling inhibitors (ARSIs) were assigned to the ARSI cohort ( N = 81).
Results
Using the Discovery cohort, independent prognostic factors of CSS, the extent of disease score ≥ 2 or the presence of liver metastasis; lactate dehydrogenase levels > 250U/L; a primary Gleason pattern of 5, and serum albumin levels ≤ 3.7 g/dl, were identified. The prognostic model incorporating these factors showed high predictability and reproducibility in the Validation cohort. The 5-year CSS of the low-risk group was 86% and that of the high-risk group was 22%. Approximately 26.4%, 62.7%, and 10.9% of the patients in the Validation cohort defined as high-risk by the LATITUDE criteria were further grouped into high-, intermediate-, and low-risk groups by the new model with significant differences in CSS. In the ARSIs cohort, high-risk group had a significantly shorter time to castration resistance than the intermediate-risk group.
Conclusions
The novel model based on prognostic factors can predict patient outcomes with high accuracy and reproducibility. The model may be used to optimize the treatment intensity of de novo mHSPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Urology, Miyazaki University Graduate School of Medicine, Miyazaki, Japan.
- Department of Urology, Tsukuba University Graduate School of Medicine, Tsukuba, Japan.
- Department of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Förderung
- Nagoya University
Zitieren
APA
Fujiwara, H., Kubota, M., Hidaka, Y., Ito, K., Kawahara, T., Kurahashi, R., Hattori, Y., Shiraishi, Y., Hama, Y., Makita, N., Tashiro, Y., Hatano, S., Ikeuchi, R., Nakashima, M., Utsunomiya, N., Takashima, Y., Somiya, S., Nagahama, K., Fujimoto, T., …, & Akamatsu, S. (2024). A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02577-1
Vancouver
Fujiwara H, Kubota M, Hidaka Y, Ito K, Kawahara T, Kurahashi R, et al. A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02577-1
BibTeX
@article{Fujiwara2024,
author = {Fujiwara, Hiroshi and Kubota, Masashi and Hidaka, Yu and Ito, Kaoru and Kawahara, Takashi and Kurahashi, Ryoma and Hattori, Yuto and Shiraishi, Yusuke and Hama, Yusuke and Makita, Noriyuki and Tashiro, Yu and Hatano, Shotaro and Ikeuchi, Ryosuke and Nakashima, Masakazu and Utsunomiya, Noriaki and Takashima, Yasushi and Somiya, Shinya and Nagahama, Kanji and Fujimoto, Takeru and Shimizu, Kosuke and Imai, Kazuto and Takahashi, Takehiro and Sumiyoshi, Takayuki and Goto, Takayuki and Morita, Satoshi and Kobayashi, Takashi and Akamatsu, Shusuke},
title = {A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02577-1}
}
EUVIMED